Ads
related to: breast cancer drug- Overall Survival Results
See Updated Overall Survival Data
For This Treatment Option
- Dosing & Administration
Read More About Dosing
And How To Prescribe
- Patient Support
View The The Service Request Form
To Gain Access To Support Programs
- Financial Resources
Learn About The Available Access
Programs For Your Patients
- Official Video Library
See A Medical Expert Discuss
Overall Survival Data For mBC
- Safety Profile
View The Full Safety Profile And
See Side Effects For This Option
- Overall Survival Results
Search results
KDM5B promotes SMAD4 loss-driven drug resistance through activating DLG1/YAP to induce lipid...
Nature· 6 days agoUpregulated KDM5B was found in PDAC, associated with poor prognosis and recurrence of PDAC patients. Upregulated KDM5B promotes PDAC tumor malignancy, i.e. cancer cells stemness ...
Antibody–peptide inhibitor conjugates: A new path for cancer therapy
Medical Xpress· 16 hours agoAn example of essential proteins hijacked by cancer cells are the cathepsins, a family of enzymes that is responsible for breaking down other proteins and remodeling the body's ...
BriaCell Doubles Progression-Free-Survival (PFS) and Reports Clinical Benefit Data at ASCO 2024
Digital Journal· 6 days ago83% intracranial objective response rate (iORR) with Bria-IMT™ in heavily pretreated advanced breast cancer patients with CNS metastasesMedian progression ...
Roche’s Sabry retires; Duchenne drug fails confirmatory test
BioPharma Dive via Yahoo Finance· 2 days agoThe veteran executive will be replaced by Boris Zaïtra. Elsewhere, Nippon Shinyaku shared negative...
Small Business - Cordele Dispatch | Cordele Dispatch
Cordele Dispatch· 16 hours agoSixteen Researchers from Florida Cancer Specialists & Research Institute Share Cancer Care Discoveries at 2024 ASCO® Annual Meeting PR Newswire FORT MYERS ...
Puma Biotechnology (PBYI) Falls 38% in 3 Months: Here's Why
Zacks· 6 days agoSales of Puma Biotechnology's (PBYI) sole marketed drug, Nerlynx, have been declining in recent quarters. Stiff competition in the target market is also a woe.
EpicentRx Announces Oral Presentation for the Most Clinically Advanced TGF-β Ligand Trap, AdAPT-001,...
ThePress.net· 6 days agoThis activity includes complete responses and several durable partial responses in established checkpoint inhibitor-resistant tumor types like sarcoma and triple negative breast< ...
Exemestane Plus Ovarian Suppression Best in Early ILC
Medscape· 6 days agoNew data add to the body of evidence favoring the aromatase inhibitor therapy plus ovarian suppression over tamoxifen for premenopausal women with early invasive lobular carcinoma.
FDA classifies Hologic’s recall of BioZorb Marker as Class I
Medical Device Network via Yahoo Finance· 7 days agoLast month, Hologic agreed to acquire Endomagnetics (Endomag), a developer of breast cancer surgery...
...Elacestrant (ORSERDU®) in Patients with ER+, HER2- MetastaticBreast Cancer (mBC) at the ASCO 2024...
FOX21 Colorado Springs· 6 days agoThe ELECTRA and ELEVATE studies were designed to overcome different resistance mechanisms and improve patient outcomes with oral-oral combination options. Updated results from the ELECTRA study ...
Ads
related to: breast cancer drug